PF-06835919, also known as MDK1846, is a potent ketohexokinase (KHK) inhibitor. PF-06835919 is reported in patent US 20170183328 A1, example 4. Increased fructose consumption and its subsequent metabolism have been implicated in hepatic steatosis, dyslipidemia, obesity, and insulin resistance in humans. Since ketohexokinase (KHK) is the principal enzyme responsible for fructose metabolism, identification of a selective KHK inhibitor may help to further elucidate the effect of KHK inhibition on these metabolic disorders.

 

Brand: BCM

 

Boiling Point: 541.2±60.0 °C(Predicted)

 

pKa: 4.66±0.10(Predicted)

 

Solubility: Soluble in DMSO; soluble in Ethanol. Insoluble in Water.

 

InChi Key: MDUYWDNWFXSMJJ-XWLWVQCSSA-N

 

Attribute
[Chem Name]	2-((1R,5S,6R)-3-(2-((S)-2-methylazetidin-1-yl)-6-(trifluoromethyl)pyrimidin-4-yl)-3-azabicyclo[3.1.0]hexan-6-yl)acetic acid
[Synonym]	PF-06835919; PF 06835919; PF06835919; MDK1846; MDK-1846; MDK 1846; ketohexokinase inhibitor; ketohexokinase-In-1
[CAS No.]	2102501-84-6
[MDL No.]	MFCD31619330
[Formula]	C16H19F3N4O2
[Molecular]	356.35
[Form]	Solid powder

Goods Tag